The initial success of Sildenafil undeniably transformed the pharmaceutical landscape, but investing in companies primarily reliant on unbranded versions presents a challenging picture. Although early profits were substantial, the expiration of patents and the emergence of less expensive alternatives have eroded market share. Therefore, a thorough